Immune Design (IMDZ) Stock: Gaining In Multiples On Acquisition News

0

Immune Design Corp (NASDAQ: IMDZ) is having an incredibly strong start to the trading session this morning, gaining in multiples after announcing acquisition news. Of course, the acquisition excited investors, pushing the stock on a run for the top. Today, we’ll talk about:

  • The acquisition;
  • what we’re seeing from IMDZ stock as a result; and
  • what we’ll be watching for ahead. 

IMDZ Flies ON Acquisition News

As mentioned above, Immune Design is having a great day in the market today after announcing acquisition news. In a press release issued early this morning, the company announced that it would be acquired by Merck. 

In the release, IMDZ said that it has entered into a definitive agreement with Merck through a subsidiary. As a result of the agreement, Merck will acquire the company at a price of $5.85 per share in cash, leading to a total value of $300 million. 

In a statement, Dr. Roger M. Perlmutter, President of Merck Research Laboratories, had the following to offer:

Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development. This acquisition builds upon Merck’s industry-leading programs that harness the power of the immune system to prevent and treat disease.

The above statement was followed up by Dr. Carlos Paya, President and CEO at IMDZ. Here’s what he had to say:

Merck has a rich history of discovery and innovation and a strong track record of developing meaningful therapeutics and vaccines. We believe this agreement creates shareholder value by positioning our technologies and capabilities for long-term success with a leading, research-driven biopharmaceutical company.

What We’re Seeing From The Stock 

One of the first lessons that we learn when wes tart to work in the market is that the news leads to moves. In the case of Immune Design, the news proved to be overwhelmingly positive. After all, not only is the company going to be acquired, the price of the acquisition represents an incredible premium. 

So, it’s not a surprise to see that investors are excited, pushing the stock up. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:32), IMDZ is trading at $5.81 per share after a gain of $4.39 per share or 309.15% thus far today. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on IMDZ. In particular, we’re interested in following the story surrounding the company’s acquisition and hoping that everything goes smoothly. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!
* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here